The Parkinson's disease therapy developer completed a series A round co-led by AbbVie Ventures, which will also take a board seat at the company.
Pharmaceutical firm AbbVie co-led a $38m series A round yesterday for Nitrome Biosciences, a US-based developer of treatments for age-related disorders, through corporate venture capital subsidiary AbbVie Ventures.
The round was co-led by VC firm Sofinnova Partners and included Alexandria Venture Investments, the VC arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as Dementia Discovery Fund and Mission Bay Capital.
Nitrome will put the series A funds into progressing its lead drug candidate, a…
